Dutch med‑robotics company Vitestro closed a $70 million Series B to commercialize Aletta, its autonomous robotic phlebotomy device designed for high‑volume diagnostic workflows. The firm said the funds will accelerate technical development, clinical pilots, manufacturing scale‑up and progress through the U.S. FDA De Novo regulatory pathway. Vitestro positions Aletta as a solution for staffing shortages and variability in blood collection, combining multimodal imaging, robotics and AI to autonomously locate veins and perform venous access. The company plans phased rollouts starting in Europe before seeking broader clinical adoption in the U.S.